ATE121785T1 - Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation. - Google Patents

Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.

Info

Publication number
ATE121785T1
ATE121785T1 AT89900028T AT89900028T ATE121785T1 AT E121785 T1 ATE121785 T1 AT E121785T1 AT 89900028 T AT89900028 T AT 89900028T AT 89900028 T AT89900028 T AT 89900028T AT E121785 T1 ATE121785 T1 AT E121785T1
Authority
AT
Austria
Prior art keywords
recombinant gene
cells
enzyme
recombinant
gene
Prior art date
Application number
AT89900028T
Other languages
English (en)
Inventor
Ray Curtiss Iii
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE121785T1 publication Critical patent/ATE121785T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01011—Aspartate-semialdehyde dehydrogenase (1.2.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT89900028T 1987-10-07 1988-10-06 Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation. ATE121785T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10607287A 1987-10-07 1987-10-07
US25130488A 1988-10-03 1988-10-03

Publications (1)

Publication Number Publication Date
ATE121785T1 true ATE121785T1 (de) 1995-05-15

Family

ID=26803271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89900028T ATE121785T1 (de) 1987-10-07 1988-10-06 Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.

Country Status (8)

Country Link
US (2) US5672345A (de)
EP (1) EP0381706B1 (de)
JP (2) JPH04501351A (de)
AT (1) ATE121785T1 (de)
AU (1) AU637969B2 (de)
CA (1) CA1339412C (de)
DE (1) DE3853683T2 (de)
WO (1) WO1989003427A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095534C (en) * 1990-11-09 2002-09-17 Roy Curtiss, Iii Avirulent microbes and uses therefor
JP3078312B2 (ja) * 1990-11-22 2000-08-21 協和醗酵工業株式会社 物質の製造法
US6566121B1 (en) * 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
WO1993019170A1 (en) * 1992-03-16 1993-09-30 Jacob Nathaniel Wohlstadter Selection methods
JPH11507532A (ja) 1995-06-07 1999-07-06 ワシントン ユニバーシティ 環境に制限される生存能を有する組換え細菌システム
US7045336B1 (en) * 1995-09-06 2006-05-16 The United States Of America As Represented By The Secretary Of The Army Bacterial delivery system
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US6537558B2 (en) 1997-03-31 2003-03-25 Megan Health, Inc. Methods of producing and using virulence attenuated poxR mutant bacteria
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
US6074825A (en) * 1997-07-31 2000-06-13 Maine Medical Center Stable encapsulated reference nucleic acid and method of making
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
EP0972838B1 (de) * 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli Wirt/Vektorsystem basierend auf einer antibiotikafreien Selektion durch Komplementation einer Auxotrophie
US6291245B1 (en) * 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
US6713073B1 (en) 1998-07-24 2004-03-30 Megan Health, Inc. Method of vaccination of newly hatched poultry
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
DE69935927T2 (de) * 1998-12-02 2008-01-10 University Of Maryland, Baltimore Plasmidstabilisierungssystem für die verabreichung von antigenen
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1223637B1 (de) 1999-09-20 2005-03-30 Fractus, S.A. Mehrebenenantenne
US6780405B1 (en) 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
US6872547B1 (en) 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
US20040137003A1 (en) * 2001-04-30 2004-07-15 Curtiss Iii Roy Regulated antigen delivery system (rads)
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
CA2526895A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
CA2624923C (en) * 2005-10-06 2016-06-07 Franck Martin Novel transformation selection system comprising pyrc gene complementation
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
US8287855B2 (en) * 2007-04-24 2012-10-16 Celldex Therapeutics, Inc. V. cholerae hyperexpressing recombinant cholera toxin B subunit showing dual immunogenicity
EP2152883A4 (de) * 2007-05-10 2010-10-27 Univ Arizona Rekombinante bakterien mit vektoren zur expression von nukleinsäuresequenzencodierenden antigenen
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US8465755B2 (en) 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
GB2483595B (en) 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US9255283B2 (en) 2010-07-02 2016-02-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Compositions and methods for bacterial lysis and neutral lipid production
BRPI1003750A2 (pt) * 2010-07-22 2012-04-10 Univ Sao Paulo microrganismos recombinantes, métodos de preparação de linhagens vacinais, antìgenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
EP3303372A2 (de) 2015-06-04 2018-04-11 Basf Se Rekombinanter mikroorganismus zur verbesserten herstellung von feinchemikalien
MX386450B (es) * 2015-06-12 2025-03-12 Basf Se Microorganismo recombinante para la producción mejorada de productos químicos finos.
WO2017142993A1 (en) * 2016-02-16 2017-08-24 Manus Biosynthesis, Inc. Secondary metabolite screening system
EP3957645A1 (de) 2016-12-20 2022-02-23 Universität Basel Virulenzabgeschwächte bakterienbasierte proteinabgabe
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
EP4725874A1 (de) 2024-10-09 2026-04-15 "Logisoft" EOOD Profilsystem für den bau von einstöckigen und mehrstöckigen förderanlagen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
WO1985003521A1 (en) * 1984-02-01 1985-08-15 Enterovax Research Pty. Ltd. Bacterial strains
DK594084A (da) * 1984-12-12 1986-06-13 Novo Industri As Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning
CA1340903C (fr) * 1986-08-05 2000-02-22 Transgene S.A. Procede de stabilisation d'un plasmide contenu dans une soche bacterienne et souche obtenue
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi

Also Published As

Publication number Publication date
AU637969B2 (en) 1993-06-17
US5672345A (en) 1997-09-30
US5840483A (en) 1998-11-24
JPH11235191A (ja) 1999-08-31
EP0381706A4 (en) 1991-09-11
AU2611188A (en) 1989-05-02
EP0381706A1 (de) 1990-08-16
EP0381706B1 (de) 1995-04-26
WO1989003427A1 (en) 1989-04-20
CA1339412C (en) 1997-09-02
JPH04501351A (ja) 1992-03-12
DE3853683T2 (de) 1995-08-31
DE3853683D1 (de) 1995-06-01

Similar Documents

Publication Publication Date Title
ATE121785T1 (de) Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.
DE69939947D1 (de) Verfahren zur herstellung von polypeptiden in mutierten aspergillus zellen
EP0945515A3 (de) Herstellung von Proteinen mittels homologer Rekombination
WO2004050827A3 (en) Cultured human pancreatic islets, and uses thereof
AU2002311989A1 (en) Methods and materials for the production of organic products in cells of $i(candida) species
ES8202362A1 (es) Procedimiento para preparar un acido desoxi-ribonucleico (adn) recombinante
DK0778348T3 (da) Fremgangsmåde til fremstilling af et protein ved anvendelse af en svamp transformeret ved multikopi-integration af en ekspr
AU1720400A (en) Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
DE69723855D1 (de) Verfahren zur herstellung von polypeptiden in surfaktinmutanten von bacillus zellen
AU4940096A (en) Host cell expressing reduced levels of a metalloprotease and methods using the host cell in protein production
CA2168037A1 (en) Transformation systems for the yeast candida utilis and the expression of heterologous genes therewith
EP1285962A1 (de) NADH-Oxidase aus Lactobacillus
ATE395424T1 (de) Verfahren zur herstellung von heterologen polypeptiden in trichothecene mangelmutanten filamentlösen pilzen
EP0248637A3 (de) Induktion von Galaktose regulierter Genexpression in Hefe
AU2002350139A1 (en) Production of cell suspensions
Hoja et al. Pleiotropic phenotype of acetyl‐CoA‐carboxylase‐defective yeast cells: Viability of a BPL1‐amber mutation depending on its readthrough by normal tRNA. esGln. rb. eiCAG. rb
EP2298911A3 (de) Verfahren zur Herstellung von Polypeptiden in atmungsdefizienten Zellen
WO1999035245A3 (en) Methods for preparing and using immortalized human neuroendocrine cells
Scheinbach Protoplast fusion as a means of producing new industrial yeast strains
DE3161317D1 (en) Process for the production of glucose dehydrogenase and microorganisms suitable therefor
EP0200565A3 (de) Verfahren zur Herstellung von Peroxydase
Arbesu et al. Isolation and characterization of Schizosaccharomyces pombe mutants lacking aminopeptidase activity
AUPQ815500A0 (en) Modification of fructan biosynthesis
GB9722481D0 (en) Expression system
FI852084L (fi) -amylaasia koodaava yhdistelmä-DNA ja menetelmiä sitä sisältävien mikro-organismien valmistamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee